Zacks: Analysts Expect Jaguar Health Inc (NASDAQ:JAGX) to Post -$5.61 EPS

Share on StockTwits

Equities research analysts expect Jaguar Health Inc (NASDAQ:JAGX) to announce earnings of ($5.61) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Jaguar Health’s earnings. The lowest EPS estimate is ($5.92) and the highest is ($5.29). Jaguar Health posted earnings of ($53.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 89.4%. The company is scheduled to issue its next quarterly earnings report on Monday, August 12th.

On average, analysts expect that Jaguar Health will report full-year earnings of ($6.07) per share for the current fiscal year, with EPS estimates ranging from ($6.23) to ($5.90). For the next year, analysts forecast that the business will report earnings of $0.03 per share, with EPS estimates ranging from $0.00 to $0.05. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Jaguar Health.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings results on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($13.29) by $0.70. Jaguar Health had a negative return on equity of 372.84% and a negative net margin of 667.59%. The company had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $2.20 million.

JAGX has been the topic of a number of analyst reports. ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Jaguar Health from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Friday, June 28th. Finally, HC Wainwright set a $10.00 price target on Jaguar Health and gave the company a “buy” rating in a research note on Tuesday, July 2nd.

In other Jaguar Health news, Director James J. Bochnowski purchased 180,582 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were bought at an average cost of $2.00 per share, for a total transaction of $361,164.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.81% of the stock is owned by company insiders.

Jaguar Health stock traded up $0.07 during midday trading on Tuesday, reaching $1.59. The company’s stock had a trading volume of 504,022 shares, compared to its average volume of 256,682. Jaguar Health has a fifty-two week low of $1.48 and a fifty-two week high of $175.00. The company has a current ratio of 0.30, a quick ratio of 0.18 and a debt-to-equity ratio of 0.02. The stock has a market cap of $7.99 million, a P/E ratio of -0.01 and a beta of 0.66. The stock’s 50-day moving average is $2.77.

About Jaguar Health

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Recommended Story: How is Preferred Stock Different from Common Stock?

Get a free copy of the Zacks research report on Jaguar Health (JAGX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.